Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MONACO trial of pimobendan in HFpEF with RV-PA uncoupling
jRCTs051210187Completed
- Sponsor
- TOA EIYO
- Start
- Jun 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of pimobendan in heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by TOA EIYO. Primary endpoint: Change in 6-minute walk distance. Started Jun 2022; status: completed.
02
Drugs
pimobendan
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on jRCTs051210187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051210187.